Tivic Health reports >65% DTC gross margin, advances VNS program with Feinstein Institute

Valion Bio, Inc.

ClearUP 2.0 launched; McKesson & Cardinal Health partnerships accelerating; customer reviews 4.4 stars; defect returns down.
D2C gross margin over 65% (vs <28% in 2023); net operating loss reduced more than 30%.
VNS pilot study with Feinstein Institute showed best-in-industry results; second study fully enrolled, data expected next year.
Targeting $30B+ annual market opportunity in non-invasive VNS; 16 issued patents, 10 pending internationally.
Plans disease-specific clinical trials in 2025, working to regain Nasdaq compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.